Previous 10 | Next 10 |
home / stock / mkgaf / mkgaf news
Summary FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. If the deal closes, the stock should rise 30%; if it fails, FSTX still has very valuable assets. The only r...
Summary Mersana has excellent ADC science. A number of big pharma have bought into the science. However, currently available data leaves a lot to be desired. Mersana ( MRSN ) is a small-cap developer of antibody drug conjugate molecules targeting oncology indications. ...
Summary The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles. To understand where opportunity may lie, I ranked the group according to various financial metrics. Read on to se...
Summary FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cancers and is already expanding indications beyond breast cancer. With this successful antibody-drug conjugate, the entire sub-industry is now seeing renewed momentum he...
Summary Big pharma performed well in 2022, but the time to trim is drawing close. As a more diversified investment, I believe former parent company of Merck & Co, Merck KGaA offers a better long-term investment. With diversification and strong fundamentals, Merck KGaA is a far b...
MERCK Kommanditgesellschaft auf Aktien (MKGAF) Q3 2022 Earnings Conference Call November 10, 2022 08:00 AM ET Company Participants Constantin Fest - Head, IR Belen Garijo - Group, CEO Marcus Kuhnert - Group CFO Matthias Heinzel - CEO, Life Science Kai Bec...
MERCK Kommanditgesellschaft auf Aktien press release ( OTCPK:MKGAF ): Q3 GAAP EPS of €2.12. Revenue of €5.8B (+16.7% Y/Y) For further details see: MERCK Kommanditgesellschaft auf Aktien GAAP EPS of €2.12, revenue of €5.8B
Merck KGaA's ( OTCPK:MKGAF ) ( OTCPK:MKKGY ) Q3 revenue was driven by its Life Science and Healthcare businesses, and the company confirmed its FY22 revenue outlook. Q3 EPS rose +21.1% Y/Y to €2.12, while EPS pre increased +19.6% Y/Y to €2.68...
Merck KGaA ( OTCPK:MKGAF ) ( OTCPK:MKKGY ) has been put under probe by a French court for allegedly issuing misleading information related to its thyroid drug Levothyrox, Reuters reported . The German drugmaker said the ruling by the judge in Marseille was not ...
Summary Using Procter & Gamble and Unilever as examples, I will show how a close look at their cash flow statements brings to light fundamental differences between the two consumer staples giants. The article provides a good understanding of the key items on a cash flow statem...
News, Short Squeeze, Breakout and More Instantly...
Merck Kgaa Company Name:
MKGAF Stock Symbol:
OTCMKTS Market:
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...